by inpharmedia | Jan 24, 2024 | Blog, Guidances, Regulatory
FDA published a new guidance in support of Drug Competition Action Plan, named “Revising ANDA Labeling Following Revision of the RLD Labeling”, providing the recommendations to tentatively approved ANDAs to help facilitate final approval on the earliest lawful... by inpharmedia | Nov 27, 2023 | Approvals, Regulatory
The U.S Food and Drug Administration (FDA) approved OGSIVEO (nirogacestat) for the treatment of progressive desmoid tumors in adults who require systemic treatment. OGSIVEO is the first drug to be approved for the treatment of patients with desmoid tumors, a rare... by inpharmedia | Feb 3, 2023 | Approvals, Regulatory
QUVIVIQ ITEMDESCRIPTIONSPONSOR/HOLDERIDORSIA PHARMACEUTICALS LTDApplication No.#214985Application TypeNDAActive IngredientDaridorexantDosage FormTABLETRoute of AdministrationORALStrengthsEQ 25mg BaseIndication for UseTreatment of adult patients with insomnia,... by inpharmedia | Feb 3, 2023 | Approvals, Blog, Regulatory
The U.S Food and Drug Administration (USFDA) has approved 04 new drugs in the month of January. Out of the 04 approvals, 03 are NDA and 01 is BLA. LEQEMBI ITEMDESCRIPTIONNDA/BLA Number:761269Applicant/Holder:EISAI INCAPI:LecanemabDosage... by inpharmedia | Feb 3, 2023 | Guidances, Regulatory
US FDA has issued a series of guidance’s to assists the sponsor and applicant in the generic drug development. The January month has around 06 new/revised guidance under GDUFA and ICH provisions. The links of the guidance’s are provided below for quick review and... by inpharmedia | Jan 3, 2023 | Guidances, Regulatory
The US FDA has issued a series of guidance’s to assists the sponsor and applicant in the generic drug development. The December month has around 04 new/revised guidance under GDUFA and ICH provisions. The links of the guidance’s are provided below for quick review and...